Reporting of Clinical Outcomes After Endovascular Aortic Aneurysm Repair: A Systematic Review

医学 腔内修复术 腹主动脉瘤 动脉瘤 梅德林 临床试验 系统回顾 主动脉瘤 腹部外科 外科 内科学 政治学 法学
作者
Harry C. Alexander,Cindy Nguyen,Adam S. J. R. Bartlett,R. H. Thomas,Alan Merry
出处
期刊:Annals of Vascular Surgery [Elsevier BV]
卷期号:77: 306-314 被引量:4
标识
DOI:10.1016/j.avsg.2021.06.006
摘要

Endovascular aneurysm repair (EVAR) is an established treatment for many patients with infra-renal abdominal aortic aneurysm (AAA). Reporting standards were published in 2002 to ensure consistent measurement and reporting of outcomes following EVAR. We aimed to assess the range of clinical outcomes reported after EVAR and whether recent studies adhere to established reporting standards.We searched MEDLINE and Embase from January 2014 until December 2018, using terms for 'EVAR' and 'AAA'. We included prospective studies and randomised controlled trials which reported clinical outcomes of elective infra-renal AAA repair. Data on clinical outcome reporting were extracted and compared with established reporting standards.84 studies were included. Technical success was reported in 49 (58.3%) studies, but only defined in 40 (47.6%), with 22 distinct definitions. Clinical success was reported and defined in 19 (22.6%) studies. Aneurysm rupture was reported in 27 (32.1%) studies and death from rupture in 11 (13.1%) studies. All-cause and aneurysm-related mortality were reported in 72 (85.7%) and 52 (61.9%) studies, respectively. Endoleak type I (n = 61, 72.6%) and II (n = 52, 61.9%) were more commonly reported than type III (n = 45, 53.6%) or IV (n = 13, 15.5%). Complications and mortality were reported by a mean of 18 (21.4%) and 42 (50%) studies, respectively.A wide variety of clinical outcomes were reported following EVAR. Few studies adhered to reporting guidelines. We recommend modification of reporting standards to reflect advances in endovascular technology and creation of a core outcome set for EVAR.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CCD发布了新的文献求助10
1秒前
优美饼干发布了新的文献求助10
1秒前
小蜜峰儿完成签到 ,获得积分10
1秒前
调皮的沛萍完成签到,获得积分10
2秒前
a553355完成签到,获得积分10
2秒前
2秒前
Jasper应助张凯采纳,获得10
2秒前
4秒前
愉快的白桃完成签到,获得积分10
4秒前
6秒前
7秒前
7秒前
pan完成签到,获得积分10
7秒前
Jasper应助科研通管家采纳,获得10
8秒前
传奇3应助科研通管家采纳,获得10
8秒前
科研通AI2S应助科研通管家采纳,获得10
8秒前
tty615应助科研通管家采纳,获得10
8秒前
JamesPei应助科研通管家采纳,获得10
8秒前
xjcy应助科研通管家采纳,获得10
8秒前
胡无敌应助科研通管家采纳,获得10
8秒前
科研通AI6应助科研通管家采纳,获得10
9秒前
tty615应助科研通管家采纳,获得10
9秒前
9秒前
water应助科研通管家采纳,获得10
9秒前
12秒前
陈某人完成签到,获得积分10
12秒前
13秒前
13秒前
文献狗完成签到,获得积分10
13秒前
khurram完成签到,获得积分10
14秒前
14秒前
14秒前
Akim应助一行白鹭采纳,获得10
15秒前
科研通AI2S应助zheng采纳,获得10
15秒前
心灵美的石头完成签到,获得积分10
18秒前
量子星尘发布了新的文献求助10
18秒前
小鱼儿发布了新的文献求助10
19秒前
dd完成签到,获得积分10
20秒前
温婉的香氛完成签到 ,获得积分10
21秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各位详细阅读】【科研通的精品贴汇总】 10000
Voyage au bout de la révolution: de Pékin à Sochaux 700
血液中补体及巨噬细胞对大肠杆菌噬菌体PNJ1809-09活性的影响 500
Methodology for the Human Sciences 500
First Farmers: The Origins of Agricultural Societies, 2nd Edition 500
Simulation of High-NA EUV Lithography 400
International socialism & Australian labour : the Left in Australia, 1919-1939 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4321624
求助须知:如何正确求助?哪些是违规求助? 3838025
关于积分的说明 11999416
捐赠科研通 3478492
什么是DOI,文献DOI怎么找? 1908083
邀请新用户注册赠送积分活动 953501
科研通“疑难数据库(出版商)”最低求助积分说明 854842